Phathom Pharmaceuticals, Inc.
PHAT
$14.60
-$0.14-0.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.12% | -11.12% | -40.21% | -65.84% | -91.70% |
| Total Depreciation and Amortization | -11.31% | 2.23% | 17.88% | 38.26% | 41.04% |
| Total Amortization of Deferred Charges | 33.11% | 27.19% | 30.13% | 16.78% | 17.75% |
| Total Other Non-Cash Items | -25.01% | -15.46% | -5.39% | 6.20% | 74.85% |
| Change in Net Operating Assets | -355.75% | -139.97% | -297.39% | -12.12% | 61.36% |
| Cash from Operations | 8.85% | -27.49% | -69.34% | -93.90% | -83.28% |
| Capital Expenditure | 75.70% | 89.07% | 92.26% | 91.74% | 61.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 75.70% | 89.07% | 92.26% | 91.74% | 61.49% |
| Total Debt Issued | -89.97% | -89.97% | -77.69% | -71.98% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.63% | 362,938.24% | -12.82% | -20.70% | -21.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -92.99% | -39.93% | -52.43% | -50.28% | 136.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -264.89% | -526.14% | -156.36% | -136.84% | 530.50% |